Cucurbitacin B suppresses hepatocellular carcinoma progression through inducing DNA damage-dependent cell cycle arrest

•CuB impeded HCC growth through inducing DNA damage dependent cell cycle arrest.•CuB did not trigger directly HCC cell death such as necrosis and apoptosis.•CuB functioned through ATM-dependent p53-p21-CDK1 and CHK1-CDC25C pathways. The mortality rate of liver cancer ranks third in the world, and he...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Phytomedicine (Stuttgart) 2024-04, Vol.126, p.155177-155177, Article 155177
Hauptverfasser: Li, Qi-Zhang, Chen, Yu-Ying, Liu, Qiu-Ping, Feng, Zhi-Hui, Zhang, Lei, Zhang, Hong
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 155177
container_issue
container_start_page 155177
container_title Phytomedicine (Stuttgart)
container_volume 126
creator Li, Qi-Zhang
Chen, Yu-Ying
Liu, Qiu-Ping
Feng, Zhi-Hui
Zhang, Lei
Zhang, Hong
description •CuB impeded HCC growth through inducing DNA damage dependent cell cycle arrest.•CuB did not trigger directly HCC cell death such as necrosis and apoptosis.•CuB functioned through ATM-dependent p53-p21-CDK1 and CHK1-CDC25C pathways. The mortality rate of liver cancer ranks third in the world, and hepatocellular carcinoma (HCC) is a malignant tumor of the digestive tract. Cucurbitacin B (CuB), a natural compound extracted from Cucurbitaceae spp., is the main active component of Chinese patent medicine the Cucurbitacin Tablet, which has been widely used in the treatment of various malignant tumors in clinics, especially HCC. This study explored the role and mechanism of CuB in the suppression of liver cancer progression. Cell Counting Kit-8 (CCK-8) and colony formation assays were used to detect the inhibitory function of CuB in Huh7, Hep3B, and Hepa1/6 hepatoma cells. Calcein-AM/propidium iodide (PI) staining and lactate dehydrogenase (LDH) measurement assays were performed to determine cell death. Mitochondrial membrane potential (Δψm) was measured, and flow cytometry was performed to evaluate cell apoptosis and cell cycle. Several techniques, such as proteomics, Western blotting (WB), and ribonucleic acid (RNA) interference, were utilized to explore the potential mechanism. The animal experiment was performed to verify the results of in vitro experiments. CuB significantly inhibited the growth of Huh7, Hep3B, and Hepa1/6 cells and triggered the cell cycle arrest in G2/M phage without leading to cell death, especially apoptosis. Knockdown of insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1), a target of CuB, did not reverse CuB elicited cell cycle arrest. CuB enhanced phosphorylated ataxia telangiectasia mutated (p-ATM) and phosphorylated H2A histone family member X (γ-H2AX) levels. Moreover, CuB increased p53 and p21 levels and decreased cyclin-dependent kinase 1 (CDK1) expression, accompanied by improving phosphorylated checkpoint kinase 1 (p-CHK1) level and suppressing cell division cycle 25C (CDC25C) protein level. Interestingly, these phenomena were partly abolished by a deoxyribonucleic acid (DNA) protector methylproamine (MPA). Animal studies showed that CuB also significantly suppressed tumor growth in BALB/c mice bearing Hepa1/6 cells. In tumor tissues, CuB reduced the expression levels of proliferating cell nuclear antigen (PCNA) and γ-H2AX but did not change the terminal deoxynucleotidyl transferase deoxyuridine triphosphate (dUTP) n
doi_str_mv 10.1016/j.phymed.2023.155177
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2932936990</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0944711323005366</els_id><sourcerecordid>2932936990</sourcerecordid><originalsourceid>FETCH-LOGICAL-c362t-b944d9d9c0eb8587acd6423483d3f5d7d5f8186c5150928536d58cc62100c24f3</originalsourceid><addsrcrecordid>eNp9kMtqHDEQRUWIicdO_iAELbPpiR4ttbQJOONHDCbZJJCd0EjVMxr6FallmL-Pmra3gYJa1Ll1qy5CHynZUkLll9N2Op578FtGGN9SIWjTvEEbKqmqiBZ_3qIN0XVdNZTyS3SV0okQWuuGvEOXXNWUSdls0PMuuxz3YbYuDPgbTnmaIqQECR9hsvPooOtyZyN2NhZk7C2e4nhYmDAOeD7GMR-OOAw-l_EB3_64wd729gCVhwkGD8OMlyXYnV0H2MYind-ji9Z2CT689Gv0-_7u1-579fTz4XF381Q5Ltlc7csDXnvtCOyVUI11XtaM14p73grfeNEqqqQTVBDNlODSC-WcZJQQx-qWX6PP695y899cjE0f0nKNHWDMyTDNS0mtSUHrFXVxTClCa6YYehvPhhKzJG5OZk3cLImbNfEi-_TikPfL7FX0GnEBvq4AlD-fA0STXIDBgQ8R3Gz8GP7v8A_xbJWu</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2932936990</pqid></control><display><type>article</type><title>Cucurbitacin B suppresses hepatocellular carcinoma progression through inducing DNA damage-dependent cell cycle arrest</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Li, Qi-Zhang ; Chen, Yu-Ying ; Liu, Qiu-Ping ; Feng, Zhi-Hui ; Zhang, Lei ; Zhang, Hong</creator><creatorcontrib>Li, Qi-Zhang ; Chen, Yu-Ying ; Liu, Qiu-Ping ; Feng, Zhi-Hui ; Zhang, Lei ; Zhang, Hong</creatorcontrib><description>•CuB impeded HCC growth through inducing DNA damage dependent cell cycle arrest.•CuB did not trigger directly HCC cell death such as necrosis and apoptosis.•CuB functioned through ATM-dependent p53-p21-CDK1 and CHK1-CDC25C pathways. The mortality rate of liver cancer ranks third in the world, and hepatocellular carcinoma (HCC) is a malignant tumor of the digestive tract. Cucurbitacin B (CuB), a natural compound extracted from Cucurbitaceae spp., is the main active component of Chinese patent medicine the Cucurbitacin Tablet, which has been widely used in the treatment of various malignant tumors in clinics, especially HCC. This study explored the role and mechanism of CuB in the suppression of liver cancer progression. Cell Counting Kit-8 (CCK-8) and colony formation assays were used to detect the inhibitory function of CuB in Huh7, Hep3B, and Hepa1/6 hepatoma cells. Calcein-AM/propidium iodide (PI) staining and lactate dehydrogenase (LDH) measurement assays were performed to determine cell death. Mitochondrial membrane potential (Δψm) was measured, and flow cytometry was performed to evaluate cell apoptosis and cell cycle. Several techniques, such as proteomics, Western blotting (WB), and ribonucleic acid (RNA) interference, were utilized to explore the potential mechanism. The animal experiment was performed to verify the results of in vitro experiments. CuB significantly inhibited the growth of Huh7, Hep3B, and Hepa1/6 cells and triggered the cell cycle arrest in G2/M phage without leading to cell death, especially apoptosis. Knockdown of insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1), a target of CuB, did not reverse CuB elicited cell cycle arrest. CuB enhanced phosphorylated ataxia telangiectasia mutated (p-ATM) and phosphorylated H2A histone family member X (γ-H2AX) levels. Moreover, CuB increased p53 and p21 levels and decreased cyclin-dependent kinase 1 (CDK1) expression, accompanied by improving phosphorylated checkpoint kinase 1 (p-CHK1) level and suppressing cell division cycle 25C (CDC25C) protein level. Interestingly, these phenomena were partly abolished by a deoxyribonucleic acid (DNA) protector methylproamine (MPA). Animal studies showed that CuB also significantly suppressed tumor growth in BALB/c mice bearing Hepa1/6 cells. In tumor tissues, CuB reduced the expression levels of proliferating cell nuclear antigen (PCNA) and γ-H2AX but did not change the terminal deoxynucleotidyl transferase deoxyuridine triphosphate (dUTP) nick-end labeling (TUNEL) level. This study demonstrated for the first time that CuB could effectively impede HCC progression by inducing DNA damage-dependent cell cycle arrest without directly triggering cell death, such as necrosis and apoptosis. The effect was achieved through ataxia telangiectasia mutated (ATM)-dependent p53-p21-CDK1 and checkpoint kinase 1 (CHK1)-CDC25C signaling pathways. These findings indicate that CuB may be used as an anti-HCC drug, when the current findings are confirmed by independent studies and after many more clinical phase 1, 2, 3, and 4 testings have been done. [Display omitted]</description><identifier>ISSN: 0944-7113</identifier><identifier>EISSN: 1618-095X</identifier><identifier>DOI: 10.1016/j.phymed.2023.155177</identifier><identifier>PMID: 38412667</identifier><language>eng</language><publisher>Germany: Elsevier GmbH</publisher><subject>Animals ; Apoptosis ; Ataxia Telangiectasia ; Ataxia Telangiectasia Mutated Proteins - genetics ; Ataxia Telangiectasia Mutated Proteins - metabolism ; Ataxia Telangiectasia Mutated Proteins - therapeutic use ; Carcinoma, Hepatocellular - drug therapy ; Carcinoma, Hepatocellular - metabolism ; Cell cycle arrest ; Cell Cycle Checkpoints ; Cell Line, Tumor ; Cell Proliferation ; Checkpoint Kinase 1 - genetics ; Checkpoint Kinase 1 - metabolism ; Checkpoint Kinase 1 - therapeutic use ; Cucurbitacin B ; DNA Damage ; Hepatocellular carcinoma ; Liver Neoplasms - drug therapy ; Liver Neoplasms - metabolism ; Mice ; Triterpenes ; Tumor Suppressor Protein p53 - metabolism</subject><ispartof>Phytomedicine (Stuttgart), 2024-04, Vol.126, p.155177-155177, Article 155177</ispartof><rights>2023 Elsevier GmbH</rights><rights>Copyright © 2023 Elsevier GmbH. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c362t-b944d9d9c0eb8587acd6423483d3f5d7d5f8186c5150928536d58cc62100c24f3</citedby><cites>FETCH-LOGICAL-c362t-b944d9d9c0eb8587acd6423483d3f5d7d5f8186c5150928536d58cc62100c24f3</cites><orcidid>0000-0002-6191-0046 ; 0000-0001-7737-7787</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.phymed.2023.155177$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>315,781,785,3551,27929,27930,46000</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38412667$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Li, Qi-Zhang</creatorcontrib><creatorcontrib>Chen, Yu-Ying</creatorcontrib><creatorcontrib>Liu, Qiu-Ping</creatorcontrib><creatorcontrib>Feng, Zhi-Hui</creatorcontrib><creatorcontrib>Zhang, Lei</creatorcontrib><creatorcontrib>Zhang, Hong</creatorcontrib><title>Cucurbitacin B suppresses hepatocellular carcinoma progression through inducing DNA damage-dependent cell cycle arrest</title><title>Phytomedicine (Stuttgart)</title><addtitle>Phytomedicine</addtitle><description>•CuB impeded HCC growth through inducing DNA damage dependent cell cycle arrest.•CuB did not trigger directly HCC cell death such as necrosis and apoptosis.•CuB functioned through ATM-dependent p53-p21-CDK1 and CHK1-CDC25C pathways. The mortality rate of liver cancer ranks third in the world, and hepatocellular carcinoma (HCC) is a malignant tumor of the digestive tract. Cucurbitacin B (CuB), a natural compound extracted from Cucurbitaceae spp., is the main active component of Chinese patent medicine the Cucurbitacin Tablet, which has been widely used in the treatment of various malignant tumors in clinics, especially HCC. This study explored the role and mechanism of CuB in the suppression of liver cancer progression. Cell Counting Kit-8 (CCK-8) and colony formation assays were used to detect the inhibitory function of CuB in Huh7, Hep3B, and Hepa1/6 hepatoma cells. Calcein-AM/propidium iodide (PI) staining and lactate dehydrogenase (LDH) measurement assays were performed to determine cell death. Mitochondrial membrane potential (Δψm) was measured, and flow cytometry was performed to evaluate cell apoptosis and cell cycle. Several techniques, such as proteomics, Western blotting (WB), and ribonucleic acid (RNA) interference, were utilized to explore the potential mechanism. The animal experiment was performed to verify the results of in vitro experiments. CuB significantly inhibited the growth of Huh7, Hep3B, and Hepa1/6 cells and triggered the cell cycle arrest in G2/M phage without leading to cell death, especially apoptosis. Knockdown of insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1), a target of CuB, did not reverse CuB elicited cell cycle arrest. CuB enhanced phosphorylated ataxia telangiectasia mutated (p-ATM) and phosphorylated H2A histone family member X (γ-H2AX) levels. Moreover, CuB increased p53 and p21 levels and decreased cyclin-dependent kinase 1 (CDK1) expression, accompanied by improving phosphorylated checkpoint kinase 1 (p-CHK1) level and suppressing cell division cycle 25C (CDC25C) protein level. Interestingly, these phenomena were partly abolished by a deoxyribonucleic acid (DNA) protector methylproamine (MPA). Animal studies showed that CuB also significantly suppressed tumor growth in BALB/c mice bearing Hepa1/6 cells. In tumor tissues, CuB reduced the expression levels of proliferating cell nuclear antigen (PCNA) and γ-H2AX but did not change the terminal deoxynucleotidyl transferase deoxyuridine triphosphate (dUTP) nick-end labeling (TUNEL) level. This study demonstrated for the first time that CuB could effectively impede HCC progression by inducing DNA damage-dependent cell cycle arrest without directly triggering cell death, such as necrosis and apoptosis. The effect was achieved through ataxia telangiectasia mutated (ATM)-dependent p53-p21-CDK1 and checkpoint kinase 1 (CHK1)-CDC25C signaling pathways. These findings indicate that CuB may be used as an anti-HCC drug, when the current findings are confirmed by independent studies and after many more clinical phase 1, 2, 3, and 4 testings have been done. [Display omitted]</description><subject>Animals</subject><subject>Apoptosis</subject><subject>Ataxia Telangiectasia</subject><subject>Ataxia Telangiectasia Mutated Proteins - genetics</subject><subject>Ataxia Telangiectasia Mutated Proteins - metabolism</subject><subject>Ataxia Telangiectasia Mutated Proteins - therapeutic use</subject><subject>Carcinoma, Hepatocellular - drug therapy</subject><subject>Carcinoma, Hepatocellular - metabolism</subject><subject>Cell cycle arrest</subject><subject>Cell Cycle Checkpoints</subject><subject>Cell Line, Tumor</subject><subject>Cell Proliferation</subject><subject>Checkpoint Kinase 1 - genetics</subject><subject>Checkpoint Kinase 1 - metabolism</subject><subject>Checkpoint Kinase 1 - therapeutic use</subject><subject>Cucurbitacin B</subject><subject>DNA Damage</subject><subject>Hepatocellular carcinoma</subject><subject>Liver Neoplasms - drug therapy</subject><subject>Liver Neoplasms - metabolism</subject><subject>Mice</subject><subject>Triterpenes</subject><subject>Tumor Suppressor Protein p53 - metabolism</subject><issn>0944-7113</issn><issn>1618-095X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kMtqHDEQRUWIicdO_iAELbPpiR4ttbQJOONHDCbZJJCd0EjVMxr6FallmL-Pmra3gYJa1Ll1qy5CHynZUkLll9N2Op578FtGGN9SIWjTvEEbKqmqiBZ_3qIN0XVdNZTyS3SV0okQWuuGvEOXXNWUSdls0PMuuxz3YbYuDPgbTnmaIqQECR9hsvPooOtyZyN2NhZk7C2e4nhYmDAOeD7GMR-OOAw-l_EB3_64wd729gCVhwkGD8OMlyXYnV0H2MYind-ji9Z2CT689Gv0-_7u1-579fTz4XF381Q5Ltlc7csDXnvtCOyVUI11XtaM14p73grfeNEqqqQTVBDNlODSC-WcZJQQx-qWX6PP695y899cjE0f0nKNHWDMyTDNS0mtSUHrFXVxTClCa6YYehvPhhKzJG5OZk3cLImbNfEi-_TikPfL7FX0GnEBvq4AlD-fA0STXIDBgQ8R3Gz8GP7v8A_xbJWu</recordid><startdate>202404</startdate><enddate>202404</enddate><creator>Li, Qi-Zhang</creator><creator>Chen, Yu-Ying</creator><creator>Liu, Qiu-Ping</creator><creator>Feng, Zhi-Hui</creator><creator>Zhang, Lei</creator><creator>Zhang, Hong</creator><general>Elsevier GmbH</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-6191-0046</orcidid><orcidid>https://orcid.org/0000-0001-7737-7787</orcidid></search><sort><creationdate>202404</creationdate><title>Cucurbitacin B suppresses hepatocellular carcinoma progression through inducing DNA damage-dependent cell cycle arrest</title><author>Li, Qi-Zhang ; Chen, Yu-Ying ; Liu, Qiu-Ping ; Feng, Zhi-Hui ; Zhang, Lei ; Zhang, Hong</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c362t-b944d9d9c0eb8587acd6423483d3f5d7d5f8186c5150928536d58cc62100c24f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Animals</topic><topic>Apoptosis</topic><topic>Ataxia Telangiectasia</topic><topic>Ataxia Telangiectasia Mutated Proteins - genetics</topic><topic>Ataxia Telangiectasia Mutated Proteins - metabolism</topic><topic>Ataxia Telangiectasia Mutated Proteins - therapeutic use</topic><topic>Carcinoma, Hepatocellular - drug therapy</topic><topic>Carcinoma, Hepatocellular - metabolism</topic><topic>Cell cycle arrest</topic><topic>Cell Cycle Checkpoints</topic><topic>Cell Line, Tumor</topic><topic>Cell Proliferation</topic><topic>Checkpoint Kinase 1 - genetics</topic><topic>Checkpoint Kinase 1 - metabolism</topic><topic>Checkpoint Kinase 1 - therapeutic use</topic><topic>Cucurbitacin B</topic><topic>DNA Damage</topic><topic>Hepatocellular carcinoma</topic><topic>Liver Neoplasms - drug therapy</topic><topic>Liver Neoplasms - metabolism</topic><topic>Mice</topic><topic>Triterpenes</topic><topic>Tumor Suppressor Protein p53 - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Li, Qi-Zhang</creatorcontrib><creatorcontrib>Chen, Yu-Ying</creatorcontrib><creatorcontrib>Liu, Qiu-Ping</creatorcontrib><creatorcontrib>Feng, Zhi-Hui</creatorcontrib><creatorcontrib>Zhang, Lei</creatorcontrib><creatorcontrib>Zhang, Hong</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Phytomedicine (Stuttgart)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Li, Qi-Zhang</au><au>Chen, Yu-Ying</au><au>Liu, Qiu-Ping</au><au>Feng, Zhi-Hui</au><au>Zhang, Lei</au><au>Zhang, Hong</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cucurbitacin B suppresses hepatocellular carcinoma progression through inducing DNA damage-dependent cell cycle arrest</atitle><jtitle>Phytomedicine (Stuttgart)</jtitle><addtitle>Phytomedicine</addtitle><date>2024-04</date><risdate>2024</risdate><volume>126</volume><spage>155177</spage><epage>155177</epage><pages>155177-155177</pages><artnum>155177</artnum><issn>0944-7113</issn><eissn>1618-095X</eissn><abstract>•CuB impeded HCC growth through inducing DNA damage dependent cell cycle arrest.•CuB did not trigger directly HCC cell death such as necrosis and apoptosis.•CuB functioned through ATM-dependent p53-p21-CDK1 and CHK1-CDC25C pathways. The mortality rate of liver cancer ranks third in the world, and hepatocellular carcinoma (HCC) is a malignant tumor of the digestive tract. Cucurbitacin B (CuB), a natural compound extracted from Cucurbitaceae spp., is the main active component of Chinese patent medicine the Cucurbitacin Tablet, which has been widely used in the treatment of various malignant tumors in clinics, especially HCC. This study explored the role and mechanism of CuB in the suppression of liver cancer progression. Cell Counting Kit-8 (CCK-8) and colony formation assays were used to detect the inhibitory function of CuB in Huh7, Hep3B, and Hepa1/6 hepatoma cells. Calcein-AM/propidium iodide (PI) staining and lactate dehydrogenase (LDH) measurement assays were performed to determine cell death. Mitochondrial membrane potential (Δψm) was measured, and flow cytometry was performed to evaluate cell apoptosis and cell cycle. Several techniques, such as proteomics, Western blotting (WB), and ribonucleic acid (RNA) interference, were utilized to explore the potential mechanism. The animal experiment was performed to verify the results of in vitro experiments. CuB significantly inhibited the growth of Huh7, Hep3B, and Hepa1/6 cells and triggered the cell cycle arrest in G2/M phage without leading to cell death, especially apoptosis. Knockdown of insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1), a target of CuB, did not reverse CuB elicited cell cycle arrest. CuB enhanced phosphorylated ataxia telangiectasia mutated (p-ATM) and phosphorylated H2A histone family member X (γ-H2AX) levels. Moreover, CuB increased p53 and p21 levels and decreased cyclin-dependent kinase 1 (CDK1) expression, accompanied by improving phosphorylated checkpoint kinase 1 (p-CHK1) level and suppressing cell division cycle 25C (CDC25C) protein level. Interestingly, these phenomena were partly abolished by a deoxyribonucleic acid (DNA) protector methylproamine (MPA). Animal studies showed that CuB also significantly suppressed tumor growth in BALB/c mice bearing Hepa1/6 cells. In tumor tissues, CuB reduced the expression levels of proliferating cell nuclear antigen (PCNA) and γ-H2AX but did not change the terminal deoxynucleotidyl transferase deoxyuridine triphosphate (dUTP) nick-end labeling (TUNEL) level. This study demonstrated for the first time that CuB could effectively impede HCC progression by inducing DNA damage-dependent cell cycle arrest without directly triggering cell death, such as necrosis and apoptosis. The effect was achieved through ataxia telangiectasia mutated (ATM)-dependent p53-p21-CDK1 and checkpoint kinase 1 (CHK1)-CDC25C signaling pathways. These findings indicate that CuB may be used as an anti-HCC drug, when the current findings are confirmed by independent studies and after many more clinical phase 1, 2, 3, and 4 testings have been done. [Display omitted]</abstract><cop>Germany</cop><pub>Elsevier GmbH</pub><pmid>38412667</pmid><doi>10.1016/j.phymed.2023.155177</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0002-6191-0046</orcidid><orcidid>https://orcid.org/0000-0001-7737-7787</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0944-7113
ispartof Phytomedicine (Stuttgart), 2024-04, Vol.126, p.155177-155177, Article 155177
issn 0944-7113
1618-095X
language eng
recordid cdi_proquest_miscellaneous_2932936990
source MEDLINE; Access via ScienceDirect (Elsevier)
subjects Animals
Apoptosis
Ataxia Telangiectasia
Ataxia Telangiectasia Mutated Proteins - genetics
Ataxia Telangiectasia Mutated Proteins - metabolism
Ataxia Telangiectasia Mutated Proteins - therapeutic use
Carcinoma, Hepatocellular - drug therapy
Carcinoma, Hepatocellular - metabolism
Cell cycle arrest
Cell Cycle Checkpoints
Cell Line, Tumor
Cell Proliferation
Checkpoint Kinase 1 - genetics
Checkpoint Kinase 1 - metabolism
Checkpoint Kinase 1 - therapeutic use
Cucurbitacin B
DNA Damage
Hepatocellular carcinoma
Liver Neoplasms - drug therapy
Liver Neoplasms - metabolism
Mice
Triterpenes
Tumor Suppressor Protein p53 - metabolism
title Cucurbitacin B suppresses hepatocellular carcinoma progression through inducing DNA damage-dependent cell cycle arrest
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-16T09%3A07%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cucurbitacin%20B%20suppresses%20hepatocellular%20carcinoma%20progression%20through%20inducing%20DNA%20damage-dependent%20cell%20cycle%20arrest&rft.jtitle=Phytomedicine%20(Stuttgart)&rft.au=Li,%20Qi-Zhang&rft.date=2024-04&rft.volume=126&rft.spage=155177&rft.epage=155177&rft.pages=155177-155177&rft.artnum=155177&rft.issn=0944-7113&rft.eissn=1618-095X&rft_id=info:doi/10.1016/j.phymed.2023.155177&rft_dat=%3Cproquest_cross%3E2932936990%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2932936990&rft_id=info:pmid/38412667&rft_els_id=S0944711323005366&rfr_iscdi=true